Synthetic Biologics, Inc.
(NYSE Amex Equities : SYN)

( )
SYN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -4.95%408.840.0%$5581.83m
BNTXBioNTech SE -7.91%307.090.0%$959.22m
NVAXNovavax, Inc. -6.90%231.0479.4%$918.58m
SNSSSunesis Pharmaceuticals, Inc. -3.24%8.370.7%$585.09m
AMGNAmgen, Inc. -0.23%213.111.4%$539.22m
GILDGilead Sciences, Inc. -1.10%70.411.0%$450.06m
REGNRegeneron Pharmaceuticals, Inc. -3.10%619.072.7%$422.20m
ILMNIllumina, Inc. -1.67%425.583.5%$353.17m
BIIBBiogen, Inc. -1.75%286.621.7%$310.33m
VRTXVertex Pharmaceuticals, Inc. -0.11%183.411.9%$248.50m
ISEEIVERIC bio, Inc. 6.90%17.500.0%$218.29m
LIFEaTyr Pharma, Inc. -3.42%9.902.1%$159.03m
BGNEBeiGene Ltd. -0.62%377.181.3%$147.82m
TECHBio-Techne Corp. -5.09%511.454.5%$138.52m
KDMNKadmon Holdings, Inc. 0.11%8.840.8%$135.49m

Company Profile

Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.